MEDICINA
Departamento
Hospital Duran i Reynals
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Duran i Reynals (60)
2024
-
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
Haematologica, Vol. 109, Núm. 2, pp. 543-552
-
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
American Journal of Hematology
-
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535
2023
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Haematologica, Vol. 108, Núm. 1, pp. 110-121
-
Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64
-
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
British Journal of Haematology, Vol. 200, Núm. 3, pp. 306-314
-
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice
Leukemia and Lymphoma, Vol. 64, Núm. 3, pp. 679-690
-
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
HemaSphere, Vol. 7, Núm. 10, pp. E961
-
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8
Cancers, Vol. 15, Núm. 15
-
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma
Journal of Clinical Oncology
-
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580
2022
-
Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC
Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols
British Journal of Haematology, Vol. 196, Núm. 3, pp. 670-675
-
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)
Microbiology Spectrum, Vol. 10, Núm. 3
-
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
2021
-
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Leukemia Research, Vol. 109
-
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Leukemia, Vol. 35, Núm. 10, pp. 2885-2894
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60